Did Eli Lilly Just Say Checkmate to Novo Nordisk?
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
Novo Nordisk (NYSE: NVO) has seen revenue soar in recent years thanks to two drugs that have helped people around the world lose weight. The molecule is semaglutide, and it’s sold under the name Ozempic for type 2 diabetes and Wegovy for weight loss — but doctors have prescribed
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2159357134-761fa1c2bc4b48cb890450528133ba86.jpg "<div>A Trade Loophole Is Closing. Here's What That Means for Your Online Shopping Costs</div>")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-13181780681-2502efd7b00e410ca9e987334296eb92.jpg "<div>American Express's Main Competition</div>")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2151268305-a63e7af07f6d48c1bf11b7959f62fb20.jpg "How Does Additional Equity Financing Affect Existing Shareholders?")
:max_bytes(150000):strip_icc():format(jpeg)/senior-manager-talks-to-the-employee-of-the-company-1026061082-5c94e85bc9e77c00015f69bc.jpg "<div>What Does a Merger or Acquisition Mean for the Target Company's Employees?</div>")
